HopeStage
Back to all studies
CompletedNCT02050854

Aripiprazole Levels in People Receiving Treatment for Bipolarity or Schizophrenia

About this title

Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia

Read the official source — NCT02050854
Observational studyAges 18–55United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 55 years.

Listed locations
Garden Grove and 4 more locationsSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateDecember 2013
Recruitment status
Completed
Enrollment listed in the registry
47
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Observational
Intervention type
Interview / survey / observational
Locations
United States
Age range
From 18 Years to 55 Years
Official registry ID
NCT02050854
Official title
Show the full official title

An Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia Who Have a History of Suboptimal Adherence and Are Currently on Treatment With Oral Aripiprazole

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Garden Grove · Atlanta · Decatur

2 more locations
  • Rockville
  • Bellevue

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Who was this study for?

Listed age limits: 18 years to 55 years.

Want to explore more studies?

Explore studies